VANCOUVER, British Columbia--(BUSINESS WIRE)--June 23, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation biocompatible stent coatings and drug delivery technologies, has announced that its proprietary Hydroxyapatite (HAp) stent coating has demonstrated excellent performance and biocompatibility in key areas assessed at the three-month follow-up stage of an ongoing study in which HAp-coated stents were implanted in pig cardiovascular arteries. The results of the study, conducted at The Methodist Hospital Research Institute in cooperation with Texas Heart Institute, pave the way for upcoming human clinical trials of HAp coatings for stents.

ADVERTISEMENT

"We are greatly encouraged with the interim results of this porcine study, which confirm our earlier observations about the superb biocompatibility and safety of our proprietary coating technologies based on Hydroxyapatite," said Alan Lindsay, CEO and Chairman of MIVT. "Successful completion of this critical arm of the animal study marks another decisive step toward the technology's readiness for human trials, and ultimately the realization of its full business potential in several multi-billion-dollar biomedical segments. Our HAp-based coating technology's unique, long-term biocompatibility and safety is among its major advantages over conventional but outdated polymer-based coatings currently available on the market."

"MIVT's D4080 Hydroxyapatite coating had no impact whatsoever on the acute operational characteristics of the stent In-vivo, including pushability, trackability, flexibility, retention on the balloon in transit and ease of deployment and removal of the delivery system," said Dr. Greg L. Kaluza, Scientific Director of the Center for Research in Cardiovascular Interventions at the Methodist Hospital Research Institute in Houston, TX, who coordinates the porcine study. "These were all on par with leading stents on the market. No elevated inflammatory response was seen in any stents coated with Hydroxyapatite in comparison to bare metal stents, suggesting excellent biocompatibility. The favorable qualitative impression on biocompatibility was complemented by low neointimal thickness and percent area stenosis," he added.

The porcine study focuses on non-drug-eluting, or "passive," HAp coating technologies. MIVT, however, also plans to apply its coating technology to other medical device products in development, as well as to other kinds of coatings, including "active" drug-eluting coatings.

"The study offers for the first time important insights into the mid-to-long-term porcine performance of MIVT's non-drug eluting, or "passive," Hydroxyapatite coating technologies applied to the cardiovascular stents and studied in an in-vivo environment," said Dr. Arc Rajtar, Vice President of Operations and coordinator of MIVT's research program. "The latest results reinforce our strategy of using this highly innovative HAp coating technology as both a drug-eluting and non-drug eluting option, and moreover, not only for cardiovascular stents, but for a variety of additional medical devices, to meet the demands for safety and long-term performance of implantable medical devices. We have a number of solutions at advanced stages of development that will combine highly controllable drug-eluting profile of novel composites with exemplary long-term biocompatibility, excellent safety and unique properties of HAp. We expect this combination of highly desirable properties to meet demands of implantable medical devices that may act also as effective drug delivery systems with minimized or completely eliminated risks and weaknesses attributable to the similar devices available at the present time."

About the Methodist Hospital Research Institute, Houston

The Methodist Hospital Research Institute is a cornerstone of The Methodist Hospital's strategic vision for its future as a top-ranked academic medical center. The Research Institute is committed to moving the latest discoveries in the laboratory to the bedside in order to provide a new standard of care for our patients in Houston and in other parts of the country. For more information on The Methodist Hospital and the Methodist Hospital Research Institute, see www.methodisthealth.com.

About MIV Therapeutics

MIV Therapeutics is developing a next generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and other implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction of metal stents. The Company's ultra-thin coating has been derived from a unique biocompatible material called hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and superior healing properties pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug eluting technology provides an alternative solution to polymer-based drug eluting coatings currently in the stent market. A broader spectrum of synthetic parameters allows The Company's drug eluting coating easily and widely applicable to various implantable devices with a pre-designed drug release profile to meet desirable clinical performance. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and supported a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of hydroxyapatite as a drug eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council - Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development program.

For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Copyright © 2005 MIV Therapeutics Inc. All rights reserved.

---

Contact:

     MIV Therapeutics Inc.
     Investors:
     604-301-9545
     Fax: 604-301-9546
     inverstor@mivtherapeutics.com
     www.mivtherapeutics.com
     or
     Product Inquiries and Business Opportunities:
     Arc Rajtar, 604-301-9545 Ext. 22
     arajtar@mivi.ca
     or
     Trilogy Capital Partners
     Paul Karon, 800-342-1467
     paul@trilogy-capital.com